COVID-19 is a rapidly evolving pandemic with critically ill^[@R1]^ patients and no proven treatments except supportive care. The 28-day mortality of critically ill COVID-19 patients is more than 60%.^[@R1]^ Older age, acute respiratory distress syndrome (ARDS),^[@R1]^ hypertension, chronic kidney disease (preprint: Cheng *et al.*, medRxiv 2020), and multisystem organ failure^[@R1]^ are risk factors for mortality. Although most critical illness occurs in older patients, younger COVID-19 patients can be critically ill.^[@R1]^ COVID-19 patients requiring intensive care have higher levels of viral shedding suggesting an association with disease severity,^[@R2]^ but the dynamics between viral clearance and recovery from severe COVID-19 remain unclear. Further, cytokine storm and hyperinflammatory state with features overlapping CAR T-cell therapy-related cytokine release syndrome (CRS) appear to be an emerging component of severe COVID-19 illness.^[@R2]^ Clinicians have few therapeutic interventions undergoing investigation for COVID-19 to supplement a patient's care. Our multidisciplinary team of cardiology, cardiothoracic surgery, hematology/oncology, infectious disease, nephrology, and pulmonary/critical care medicine present a successful report of VV-ECMO support for COVID-19 respiratory failure in North America while targeting hyperinflammation.

Case Report
===========

On March 11, an active 44-year-old male with known COVID-19 contacts and a family member with a viral prodrome presented with a 3-day history of shortness of breath and fever. Pertinent medical history included hypertension (on lisinopril) and hyperlipidemia (on atorvastatin). Pulse was 135 bpm, temperature 39.5°C, blood pressure 159/91 mm Hg, respiratory rate 20 breaths/minute, and oxygen saturation 95% on room air. The examination was otherwise unremarkable. Lab results were notable for lymphopenia (450 cells/µL). Chest x-ray revealed a small right upper lobe infiltrate. A viral panel and PCR for SARS-CoV-2 were negative. He was discharged on azithromycin and cefuroxime for community-acquired pneumonia.

Twenty-four hours later, he returned with persistent fever and worsening dyspnea. On examination, he remained tachycardic, febrile, and hypertensive with mildly increased work of breathing and diffuse rhonchi, but now oxygen saturation 96% on 3 L/min oxygen. Laboratories revealed worsening lymphopenia (370 cells/µL) and elevated C-reactive protein (415 mg/L). Repeat PCR for SARS-CoV-2 returned positive. He worsened rapidly requiring endotracheal intubation, lung-protective ventilation, inhaled epoprostenol, pronation within 12 hours, and escalation in fraction of inhaled oxygen (FiO~2~) to 80% and positive end-expiratory pressure (PEEP) to 14 cm H~2~O. At the time of pronation, his partial pressure of arterial oxygen (PaO~2~):FiO~2~ ratio was 104. He did not require paralysis. Transthoracic echocardiogram was normal. He was continued on azithromycin and ceftriaxone and treated with hydroxychloroquine 400 mg daily. He developed worsening PaO~2~:FiO~2~ (nadir 84), acute kidney injury, and abrupt onset hypotension that required dobutamine 5 µg/kg/min and norepinephrine 15 µg/min. He stabilized hemodynamically and LVEF on dobutamine 2.5 µg/kg/min was 50%. Creatine kinase increased from 312 to 1,582 units/L. Troponin was negative. Interleukin (IL)-6 was severely elevated (2,436.7 pg/ml, resulted hospital day 14). Based on the Extracorporeal Life Support Organization guidelines ([www.elso.com](www.elso.com)), he met indication for VV-ECMO: hypoxemic respiratory failure with 80% mortality risk as predicted by PaO~2~:FiO~2~ \<100 despite optimal care, and was transferred on hospital day 4 (ECMO day 0). On arrival, vasoactive medications included dobutamine 2.5 µg/kg/min, norepinephrine 6 µg/min, and epoprostenol 50 ng/kg/min, with pulse 105 bpm, arterial blood pressure 125/46 mm Hg, oxygen saturation 90% on 100% FiO~2~ with tidal volume 6 ml/kg, and PEEP 16 cm H~2~O. Arterial blood gas showed pH 7.292, partial pressure of carbon dioxide 45.7 mm Hg, and PaO~2~ 84 mm Hg (PaO~2~:FiO~2~ 84).

We confirmed normal biventricular function by echocardiogram, initiated femoral-femoral VV-ECMO (4.8 L/min, 3,700 rpm, 100% FiO~2~, sweep 4 L/min), and started continuous renal replacement therapy (CRRT). ECMO configuration: Quadrox-ID adult oxygenator and Levitronix Centrimag device, 25F multistage cannula with tip the cavoatrial junction, and 21F multistage cannula in the abdominal inferior vena cava. We used a bifemoral approach to avoid instrumentation near the airway and the need for transesophageal echocardiography used in single cannula configuration.

His oxygen saturation increased to 97% and PaO~2~ to 100 mm Hg without changing ventilation settings. Repeat IL-6 was severely elevated (\>3,000 pg/ml, resulted on hospital day 19). He was continued on hydroxychloroquine 400 mg daily, azithromycin, and ceftriaxone.

By ECMO day 1, he was off epoprostenol, dobutamine, and norepinephrine; on 70% FiO~2~ with PaO~2~ 72 mm Hg; and on cisatracurium. Laboratory evaluation was notable for lymphopenia, marked elevation in C-reactive protein, and hyperferritinemia (**Table 1**). We initiated tocilizumab 800 mg every 8 hours for 3 doses, started hydralazine and clonidine for hypertension, and removed net 2 L of fluid with CRRT.

On ECMO day 3, C-reactive protein decreased substantially, lymphopenia resolved (**Figure [1](#F1){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**), and antibiotic therapy completed. Lung function started to improve based on reduced ventilator FiO~2~ and ECMO sweep requirements (**Figure [2](#F2){ref-type="fig"}**).

###### 

Clinical Laboratory Results
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![Temporal relationship of tocilizumab and high-dose vitamin C therapy during VV-ECMO therapy with selected clinical laboratory results. The first dose of tocilizumab is denoted with a single dashed line and vitamin C with an alternating dashed line. A: C-reactive protein. B: Absolute lymphocyte count. C: Ferritin. VV-ECMO, venovenous extracorporeal membrane oxygenation.](mat-publish-ahead-of-print-10.1097.mat.0000000000001177-g002){#F1}

![Temporal relationship of tocilizumab and high-dose vitamin C therapy during VV-ECMO therapy with oxygenation, mechanical ventilation, and ECMO parameters. The first dose of tocilizumab is denoted with a single dashed line and vitamin C with an alternating dashed line. A: Partial pressure of arterial oxygen to fraction of inhaled oxygen ratio (PaO~2~:FiO~2~). B: Fraction of inhaled oxygen (FiO~2~) on the ventilator and ECMO circuit. C: Positive end-expiratory pressure (PEEP, cm H~2~O) and tidal volume indexed to ideal body weight (ml/kg). D: ECMO flow rate and sweep speed. VV-ECMO, venovenous extracorporeal membrane oxygenation.](mat-publish-ahead-of-print-10.1097.mat.0000000000001177-g003){#F2}

On ECMO day 4, we started high-dose vitamin C 5,000 mg every 6 hours. His condition rapidly improved and given an anticipated supply shortage, we discontinued hydroxychloroquine. By ECMO day 7, he was on 21% FiO~2~ on the ECMO circuit, sweep 0.5 L/min, PEEP 10 cm H~2~O, and tidal volume 6 ml/kg (**Figure [2](#F2){ref-type="fig"}**). We successfully decannulated him after 160 hours of VV-ECMO support and extubated him 4 days later. Repeat SARS-CoV-2 test was negative on hospital day 21. On hospital day 24, he was discharged home without need for supplemental oxygen or renal replacement therapy.

Discussion
==========

We postulate that support with VV-ECMO, mechanical ventilation, and CRRT provided time for our patient to benefit from: (1) hydroxychloroquine possibly reduced viral load; (2) IL-6 receptor blockade likely abrogated hyperinflammation; and (3) high-dose vitamin C possibly reduced inflammation and enhanced lung recovery. Further, anecdotal data indicate that no COVID-19 patient with multiorgan failure has survived ECMO, prompting several institutions to set multiorgan failure as a contraindication. Based on our patient, multiorgan failure including acute renal failure may not signify an insurmountable scenario to contraindicate the use of VV-ECMO in COVID-19 patients.

Remdesivir is an investigational antiviral agent in COVID-19; however, it was contraindicated in our patient. A recent study reported a reduced detection of SARS-CoV-2 RNA in upper respiratory tract specimens from patients treated with hydroxychloroquine.^[@R3]^ Hydroxychloroquine may also suppress proinflammatory cytokines (Tumor Necrosis Factor \[TNF\]-alpha and IL-6) associated with coronavirus-induced ARDS.^[@R4]^ Based on this information and limited anecdotal data, we treated our patient with hydroxychloroquine. In our patient, IL-6 levels continued to rise despite being on hydroxychloroquine and we cannot determine what effect hydroxychloroquine had, if any, on IL-6 levels.

Cytokine profiling from 40 COVID-19 patients from Wuhan, China demonstrated increased IL-1, monocyte chemotactic protein-1, TNF-alpha, IL-6, C-reactive protein, and ferritin levels (preprint: Liu *et al*., MedRxiv 2020). C-reactive protein expression is induced by IL-6, is increased in CRS, and may be clinically relevant as a marker of IL-6 activity.^[@R5]^ Tocilizumab, an IL-6 receptor antagonist, is FDA approved and used in the management of CAR T-cell--related CRS.^[@R5]^ Based on partial clinical and biologic overlap with CRS, there is biologic plausibility to administer tocilizumab in severe and critical illness due to COVID-19. In support of this, 19 of 21 severely and critically ill COVID-19 patients in China treated with tocilizumab survived to discharge and \>80% had improved fever, supplemental oxygenation needs, or inflammatory markers (preprint: Xu *et al*., ChinaXiv 2020).

Chinese CDC oxygenation criteria for severe illness in COVID-19 parallel the ASTCT criteria for grade 2 CRS, essentially requiring supplemental oxygen, whereas the criteria for critical illness in COVID-19 parallel the ASTCT criteria for grade 4 CRS, including patients with shock or requiring mechanical ventilation. In clinical trials, grade 4 CRS is reversible in all patients treated with tocilizumab 8 mg/kg (maximum dose 800 mg) every 8 hours, maximum 3 doses in 24 hours.^[@R6]^ Given the critical illness in our patient, we used this dosing regimen. After administration of tocilizumab, our patient had a rapid and sustained decrease in C-reactive protein (**Figure [1](#F1){ref-type="fig"}**). This demonstrates that tocilizumab given while on VV-ECMO is effective at blocking IL-6 signaling. The progressive improvement in oxygenation and decannulation from ECMO suggests blocking excessive IL-6 activity facilitates recovery from COVID-19 respiratory failure.

Vitamin C may also reduce the proinflammatory state and be beneficial in recovery of acute lung injury based on animal data.^[@R7]^ Although the CITRIS-ALI study^[@R8]^ failed to demonstrate improvement in sepsis-related ARDS with vitamin C in primary endpoints, secondary analysis suggested lower mortality and more intensive care unit-free days with vitamin C (*p* \< 0.05). Based on anecdotal reports on COVID-19 patients (reference not available), potential benefit, and lack of adverse effects,^[@R8]^ we elected to treat our patient with high-dose intravenous vitamin C using the CITRIS-ALI protocol.^[@R8]^ The rapid improvement in oxygenation and lung compliance in our patient after initiation of high-dose vitamin C is impressive but could be coincidental.

Because of the rapid recovery of our patient, it is enticing to speculate that targeting hyperinflammation in critical COVID-19 illness will reduce the duration of support needed from VV-ECMO and/or mechanical ventilation. However, the applicability of our single-patient experience must be cautioned. Neither tocilizumab nor vitamin C is FDA approved for use in COVID-19 patients, and further investigation is needed to determine their benefit. Accordingly, our patient has been added to the Real world Evidence for Anti-Cytokine Therapy in COVID-19 Registry.
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